Andrew Benjamin Nixon, PhD

Professor in Medicine
Member of the Duke Cancer Institute
Campus mail 133 Jones, Research Drive, Durham, NC 27710
Phone (919) 613-7883
Email address anixon@duke.edu

Andrew Nixon, PhD, MBA (Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Education and Training

  • M.B.A., Duke University, 2007
  • Ph.D., Wake Forest University, 1997

Grants

Publications

Jia, Jingquan, Donna Niedzwiecki, Christy Arrowood, Nancy Garett-Mead, Rebecca Nagy, Richard B. Lanman, John Wright, Andrew B. Nixon, and John H. Strickler. “A phase II study of savolitinib (volitinib, AZD6094, HMPL-504) in subjects with MET amplified metastatic colorectal cancer (mCRC) detected by cell-free (cf)DNA.” In Journal of Clinical Oncology, Vol. 38, 2020.

Scholars@Duke

Reed, Christopher Robert, Christopher Cameron McCoy, Uttara Nag, Andrew B. Nixon, James Otto, Jeffrey Harold Lawson, Andrew J. Lodge, Joseph W. Turek, and Elisabeth Tomlinson Tracy. “Proteomic Analysis of Infants Undergoing Cardiopulmonary Bypass Using Contemporary Ontological Tools.” J Surg Res 246 (February 2020): 83–92. https://doi.org/10.1016/j.jss.2019.08.019.

PMID
31562990
Full Text

Nixon, Andrew B., Kurt A. Schalper, Ira Jacobs, Shobha Potluri, I-Ming Wang, and Catherine Fleener. “Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?” J Immunother Cancer 7, no. 1 (November 27, 2019): 325. https://doi.org/10.1186/s40425-019-0799-2.

PMID
31775882
Full Text

Strickler, John H., Christel N. Rushing, Donna Niedzwiecki, Abigail McLeod, Ivy Altomare, Hope E. Uronis, S David Hsu, et al. “A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.” Bmc Cancer 19, no. 1 (November 1, 2019): 1032. https://doi.org/10.1186/s12885-019-6234-8.

PMID
31675952
Full Text

Arrillaga-Romany, Isabel, Solmaz Sahebjam, David Picconi, Jian Campian, Pierre Giglio, Jan Drappatz, Robert Aiken, et al. “A RANDOMIZED PHASE 2 TRIAL OF CEDIRANIB IN COMBINATION WITH OLAPARIB VERSUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA.” In Neuro Oncology, 21:27–27. OXFORD UNIV PRESS INC, 2019.

Scholars@Duke

George, Daniel J., Susan Halabi, Patrick Healy, Ian Barak, Carolyn Winters, Monika Anand, Rhonda Wilder, et al. “Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.” Prostate 79, no. 15 (November 2019): 1752–61. https://doi.org/10.1002/pros.23899.

PMID
31497882
Full Text

Mettu, N. B., E. Twohy, F. -. S. Ou, T. R. Halfdanarson, H. J. Lenz, R. Breakstone, P. M. Boland, et al. “BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study.” In Annals of Oncology, Vol. 30. OXFORD UNIV PRESS, 2019.

Scholars@Duke

Corradetti, Michael N., Jordan A. Torok, Ace J. Hatch, Eric P. Xanthopoulos, Kyle Lafata, Corbin Jacobs, Christel Rushing, et al. “Dynamic Changes in Circulating Tumor DNA During Chemoradiation for Locally Advanced Lung Cancer.” Adv Radiat Oncol 4, no. 4 (October 2019): 748–52. https://doi.org/10.1016/j.adro.2019.05.004.

PMID
31673668
Full Text

Clarke, Jeffrey Melson, Gerard C. Blobe, John H. Strickler, Hope Elizabeth Uronis, S Yousuf Zafar, Michael Morse, Evan Dropkin, et al. “A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial).” Cancer Chemother Pharmacol 84, no. 4 (October 2019): 909–17. https://doi.org/10.1007/s00280-019-03916-0.

PMID
31444620
Full Text

Sharma, Mayur, Cathy Schilero, David M. Peereboom, Brian P. Hobbs, Paul Elson, Glen H. J. Stevens, Keith McCrae, Andrew B. Nixon, and Manmeet S. Ahluwalia. “Phase II study of Dovitinib in recurrent glioblastoma.” J Neurooncol 144, no. 2 (September 2019): 359–68. https://doi.org/10.1007/s11060-019-03236-6.

PMID
31292802
Full Text

Pages